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DOI 10.1016/j.chembiol.2011.07.011SUMMARY tive third (L3) stage. Infectious L3 invade host skin andmigrate toThe screening of bioactive compound libraries can
be an effective approach for repositioning FDA-
approved drugs or discovering new pharmaco-
phores. Hookworms are blood-feeding, intestinal
nematode parasites that infect up to 600 million
people worldwide. Vaccination with recombinant
Ancylostoma ceylanicum macrophage migration
inhibitory factor (rAceMIF) provided partial protec-
tion from disease, thus establishing a ‘‘proof-of-
concept’’ for targeting AceMIF to prevent or treat
infection. A high-throughput screen (HTS) against
rAceMIF identified six AceMIF-specific inhibitors.
A nonsteroidal anti-inflammatory drug (NSAID),
sodiummeclofenamate, could be tested in an animal
model to assess the therapeutic efficacy in treating
hookworm disease. Furosemide, an FDA-approved
diuretic, exhibited submicromolar inhibition of
rAceMIF tautomerase activity. Structure-activity
relationships of a pharmacophore based on furose-
mide included one analog that binds similarly to the
active site, yet does not inhibit the Na-K-Cl sym-
porter (NKCC1) responsible for diuretic activity.
INTRODUCTION
Hookworms are hematophagous, intestinal nematodes that
exact a particularly devastating toll on young children and
women of childbearing age by causing severe anemia and
protein malnutrition. Themajority of human hookworm infections
are caused by Ancylostoma duodenale, A. ceylanicum, and
Necator americanus (Bungiro and Cappello, 2004; Hotez et al.,
2004). For each hookworm species, the life cycle begins when
eggs are excreted in the feces of an infected individual onto
warm, moist soil. The eggs hatch, releasing a first stage hook-
worm larva (L1), which undergoes successive molts to the infec-Chemistry & Biology 18, 1089–110the lungs via the vasculature. After breaking out of the alveolar
spaces and ascending the bronchial tree, the larvae are coughed
up and swallowed by the host. Upon reaching the small intestine,
the larvae molt to become adult worms, where they attach to the
intestinal mucosa, ingest blood and tissue and begin to produce
eggs. In heavily infected individuals with low dietary iron intake,
the associated blood loss can rapidly lead to chronic hookworm
disease, characterized by severe anemia, malnutrition, and
growth/cognitive delay in children (Stephenson, et al., 2000).
Nearly 600 million people are infected by hookworms, virtually
all of whom live in resource-limited countries (Bethony et al.,
2006; de Silva et al., 2003). Although treatment for hookworm
disease is available, there is concern about drug resistance
and the lack of late-stage development of novel therapeutics
(Albonico et al., 2004). In addition, there are commercial chal-
lenges in supporting drug development for this parasitic disease.
Drug repositioning is an effective mechanism tomeet these chal-
lenges if there are currently used drugs that possess anthel-
minthic activity.
Macrophage migration inhibitory factor (MIF) is a mammalian
cytokine involved in innate and adaptive immunity that plays
multiple roles in the inflammatory response (Guo et al., 2009;
Roger et al., 2001). MIF functions by activating the CD74/CD44
receptor complex, which signals through a Src kinase, resulting
in the phosphorylation of the ERK-1/2, production of PGE2, and
counter-regulation of corticosteroid activity, among other intra-
cellular signaling events (Leng et al., 2003; Lolis 2001; Shi et al.,
2006).MIF has also been shown to activate the chemokine recep-
tors CXCR2 and CXCR4, and has a role in the development of
atherosclerosis (Bernhagen et al., 2007). In contrast tomost other
cytokines, MIF is present in the cytosol and is released upon
cellular stimulation (Kleemann et al., 2000; Merk et al., 2009).
Also, MIF is expressed in a wide range of mammalian tissue and
cell types as well as across a wide range of taxa including both
free-living and parasitic nematodes (Esumi et al., 1998; Leng
et al., 2003; Sato et al., 2003; Vermeire et al., 2008). Finally, struc-
tural studies reveal that MIF forms a homotrimer with three cata-
lytic sites, each between two subunits, with structural similarity
to two microbial enzymes—4-oxalocrotonate tautomerase and1, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1089
Figure 1. Immunization of Hamsters with Recombinant AceMIF
Followed by Challenge with Ancylostoma Ceylanicum Hookworms
Hamsters (5/group) were immunized subcutaneously with 100 mg rAceMIF in
the adjuvant alum, whereas controls received alum only. After boosting twice
with 50 mg of rAceMIF, animals were challenged with 100 A. ceylanicum
infective larvae and monitored for 40 days. As shown in (A), immunization of
hamsters with rAceMIF was associated with partial protection from hook-
worm-associated growth delay, with significantly higher bodyweights noted at
days 26–40 post infection (p < 0.03) compared with controls. In (B), immunized
animals also exhibited less severe anemia after challenge infection, with higher
blood hemoglobin levels from days 23–33 postinfection (p < 0.05).
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et al., 1996; Sun et al., 1996; Suzuki et al., 1996). MIF has tauto-
merase activity on ‘‘model’’ substrates such as a 2-carboxy-2,3-
dihydroindole-5,6-quinone (L-dopachrome) and hydroxyphenyl-
pyruvate (HPP) (Rosengren et al., 1996, 1997). Small molecule
binding within the active site of mammalian MIF active site
reduces cellular (Lubetsky et al., 2002; Swope et al., 1998) and
in vivo biological activity, providing a therapeutic effect in
a number of diseases in mouse models including sepsis, colitis,
and lupus among others (Crichlow et al., 2007; Dagia et al.,
2009; Leng et al., 2011).
In our previous work, the cDNA of a MIF homolog from
A. ceylanicum (AceMIF) was cloned and the recombinant protein
was expressed and functionally characterized, and its three-
dimensional structure determined by X-ray crystallography
(Cho et al., 2007). In vitro experiments revealed AceMIF has tau-1090 Chemistry & Biology 18, 1089–1101, September 23, 2011 ª201tomerase activity and binds the MIF receptor, CD74, suggesting
a role in modulating host immune responses to hookworm
infection. Importantly, an inhibitor of human MIF, (S,R)-3-(4-
hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acidmethyl ester
(ISO-1), did not inhibit AceMIF tautomerase or chemoattractant
activities, suggesting that differences in the enzymatic sitesmight
allow for identification of specific inhibitors of AceMIF.
Recently the issue of repositioning FDA-approved drugs for
new indications has gained significant attention as a result of
the time and cost necessary in bringing a novel drug into clinical
use (Chong and Sullivan, 2007). Here we report the results of
a high throughput screening (HTS) of a clinically active, small
molecule library against AceMIF on the basis of the inhibition
of tautomerase activity. We tested the effect of each inhibitor
in three assays to choose a compound for further therapeutic
development: inhibition of (1) catalytic activity, (2) binding to
the MIF receptor, CD74, and (3) AceMIF-mediated monocyte
migration. We also examined the toxicity of the compounds in
an ex vivo worm-killing assay. Analyses of the results allowed
us to choose one inhibitor compound with activities in assays
1-3 for repositioning and another inhibitor with activities against
all four assays for further structure-activity and crystallographic
studies, forming the basis for future structure-based drug design
and in vivo studies with a hamster model of hookworm disease
(Bungiro et al., 2001; Cappello et al., 2006; Garside and Behnke
1989).
RESULTS
AceMIF Immunization
To test whether neutralization of AceMIF would impact hook-
worm-induced pathogenesis, Syrian hamsters were immunized
with rAceMIF and followed for changes in bodyweight and blood
hemoglobin levels after hookworm infection. Hamsters were
immunized subcutaneously with 100 mg of rAceMIF in alum adju-
vant, whereas controls received alum only. After boosting (50 mg
of rAceMIF 2X), animals were challenged with 100 A. ceylanicum
infective larvae and monitored for 40 days. As shown in Fig-
ure 1A, immunization of hamsters with rAceMIF was associated
with partial protection from hookworm-associated growth delay
and with significantly higher body weights noted at days 26–40
postinfection (p < 0.03) compared with controls. Immunized
animals also exhibited less severe anemia after challenge infec-
tion, with higher blood hemoglobin levels noted from days 23–33
postinfection (Figure 1B, p < 0.05). The demonstration that vacci-
nation confers partial protection from clinical symptoms of hook-
worm-associated disease (weight loss and anemia) suggests
that AceMIF, which is secreted by adult A. ceylanicum, is an
important virulence factor that plays a role in pathogenesis. It
also suggests that AceMIF is accessible by antibodies in the
bloodstream of infected animals and therefore could be targeted
using small molecule inhibitors. In previous studies, inhibitors
targeting the catalytic site of humanMIFwere therapeutic in vivo,
further providing a rationale for inhibiting this site of AceMIF (Cri-
chlow, et al., 2007; Dagia et al., 2009; Leng et al., 2011).
Inhibitors from a Chemical Library
A HTS assay of L-dopachrome tautomerase activity (Z0 [Equa-
tion S1] value > 0.8) was developed for AceMIF using an1 Elsevier Ltd All rights reserved
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chemical library composed of FDA-approved drugs and other
bioactive compounds (GenPlus, MicroSource, Gaylordsville,
CT) (Zhang et al., 1999). The rationale for developing this assay
was based on previous studies that identified small molecules
that bind theMIF active site and have proven to have therapeutic
effect in animal models of disease (Crichlow et al., 2007; Dagia
et al., 2009; Leng et al., 2011). Eleven compounds that inhibited
AceMIF L-dopachrome tautomerase activity by more than 60%
relative to controls in the HTS assay were selected and
purchased for laboratory studies. Five of those that also inhibited
human MIF or were false positives were removed from further
characterization. Cross-reactivity of the six remaining AceMIF
inhibitors (Table 1 was studied using the HPP tautomerase assay
against human MIF and the Ki’s were 3–104-fold greater than
AceMIF) (see Table S1 available online). Human MIF-mediated
peripheral blood mononuclear cell (PBMC) migration was not
significantly inhibited by any compound. Interaction of human
MIF with sCD74 was also not inhibited by any of the compounds.
Among these six compounds were: pyrantel pamoate
(compound 4) and hexylresorcinol (compound 6), two com-
pounds with anthelminthic properties; sodium meclofenamate
(compound 1), a NSAID; furosemide (compound 2), a diuretic
used to treat hypertension and heart failure; hydroxyzine pa-
moate (compound 3), an anti-anxiety medicine; and cobalamine
(compound 5). We also performed a meta-analysis of 15 unre-
lated screens performed at the Yale Center for Proteomics and
Genomics to characterize the specificity of the GenPlus library.
Hexachlorophene was common in six different assays, including
MIF, and was excluded from further studies with AceMIF. Of the
compounds, 1, 2, 4, 5, and 6 were common in another screen for
antioxidants. Compound 3was common in two screens (Supple-
mental Experimental Procedures).
Kinetic Properties of the Inhibitors
For extensive kinetic studies, HPP was used as a substrate
instead of L-dopachrome, which is stable for only 20–30 min at
ambient temperatures. Initial velocities of AceMIF tautomerase
activity with three different inhibitor concentrations and HPP
concentrations ranging from 0.01–2 mM were measured and
analyzed to determine the inhibition type using Lineweaver-
Burk plot analysis. In two recent studies, inhibitors were found
to bind to an allosteric site adjacent to the active site and function
as noncompetitive inhibitors (Cho et al., 2010; McLean et al.,
2010). Representative graphs of a competitive, noncompetitive,
andmixed inhibition are shown in Figures 2A–2C, respectively. A
complete summary of Ki’s and inhibition types of all the inhibitors
is listed in Table 1. Compounds 1, 2, and 4 are competitive inhib-
itors, with Ki’s in the sub- to micromolar range. Compounds 3
(Ki 5.71 mM) and 6 (Ki 136.6 mM) are both mixed inhibitors with
varied Ki’s. Compound 5was determined to be a noncompetitive
inhibitor of AceMIF tautomerase activity andhad aKi of 124.4mM.
Inhibition of AceMIF-Induced Chemotaxis
Chemotaxis assays with human PBMCs were performed at
a single concentration of AceMIF with an excess of each
compound (Figure 2D and Table 2). Interestingly, the antichemo-
tactic activity of inhibitor compounds did not correlate with the
potency of enzymatic inhibition. For example, compound 5 (KiChemistry & Biology 18, 1089–110of 124.4 mM) was a more potent antichemotactic agent than
compounds 2, 3, and 4, which had Ki’s from 0.56–8.16 mM. It
is clear from Figure 2D that the type of inhibition also bears no
relevance to the potency of antichemotactic activity because
competitive, noncompetitive, and mixed inhibitors (compounds
1, 2, 4, 5, and 6) are all potent inhibitors of AceMIF-mediated
monocyte chemotaxis. For compound 2, a dose-dependent inhi-
bition assay was performed to estimate an IC50 value, which was
approximately 1 mM (Figure S1).
Inhibition of AceMIF Binding to the Human
CD74 Receptor
AceMIF interactswith the humanMIF receptorCD74, presumably
to modulate and potentially evade the host immune response
(Choet al., 2007). To determinewhether anyof the inhibitorsblock
the binding of AceMIF to CD74, we used the same method as
previously described to detect interactions with the immobilized
soluble extracellular domain (residues 73–232) of CD74 (sCD74)
(Leng et al., 2003). Compounds 2, 4, and 6 specifically interfered
with AceMIF interactions with sCD74 at submicromolar IC50s
(Table 1). A representative dose-response graph of compound 2
is shown in Figure 2E.
Worm-Killing Assays
The anthelminthic activity of each of the inhibitors was tested
against A. ceylanicum in an ex vivo worm-killing assay (Cappello
et al., 2006). The rationale for these experiments was based on
the presence of AceMIF in homogenates of L3 larvae and adult
A. ceylanicum (Cho et al., 2007), and that AceMIF may serve
a worm-specific function(s) in the absence of host immune effec-
tors, similar to that of human MIF (Mitchell et al., 2002). These
experiments were also important in evaluating the nematicidal
potential of each compound for future in vivo studies. Survival
curves of AceMIF inhibitor-treated worms were significantly
different from control worms treated with dimethyl sulfoxide
(DMSO) alone (Table 1 and Figure 2F; compound 2, p = 0.0007;
compound 3, p = 0.0005; compound 4, p = 0.0023). However,
survival curves of these compounds were not significantly
different fromeachother.Compounds2,3,and4 inhibitedsurvival
with 40%–50% worm-killing activity. All other compounds,
including compound 1, the most potent enzymatic inhibitor, had
worm-killing activity of 0%–15%, indicating that the blocking
AceMIF active site is insufficient to kill hookworms ex vivo.
Structure-Activity Relationships of Compound 2
Compound 2 exhibited the best combination of inhibitory activi-
ties—submicromolar for both the Ki for enzyme activity (binding
to the AceMIF active site) and IC50 for CD74 receptor binding,
IC50 of 1 mM inmonocyte chemotaxis experiments, and the largest
effect in the worm-killing assay. Therefore, compound 2 was
selected for further study. To investigate the contribution of each
functional group of compound 2 in its inhibitory effect, structurally
similarmoleculeswereselected fromasearchofPubChem (http://
pubchem.ncbi.nlm.nih.gov/) and assayed for comparison. Chem-
ical structures and kinetic parameters of these structural analogs
are shown in Table 1. Compound 9 (2-(furan-2-ylmethylamino)
benzoic acid) and compound 2 have furfurylamine at the R1 posi-
tion and have relatively low Ki values compared with compound
7 (4-chloro-5-(furan-2-ylmethylsulfamoyl)-2-piperidin-1-ylbenzoic1, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1091
Table 1. AceMIF Inhibitors Identified from HTS and Structural Similarity Search
No Structure
Tautomerase activity
inhibition (mM)
PBMC migration
inhibition (%)
CD74 binding
inhibition (mM)a
Worm-killing
(%)
1 0.47(C) 100 34% 0
2 0.56(C) 89 0.33 50
3 5.71(M) 7 25% 50
4 8.16(C) 76 0.09 40
5 124.4(NC) 94 6% 0
6 136.6(M) 57 0.66 0
7 247.0(NC) 42 38% 0
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Table 1. Continued
No Structure
Tautomerase activity
inhibition (mM)
PBMC migration
inhibition (%)
CD74 binding
inhibition (mM)a
Worm-killing
(%)
8 44.0(NC) 82 3.3 0
9 2.37(C) 82 15% 0
10 24.8(C) 35 9% 0
11 5.0(C) 19 2% 0
12 7.7(C) 50 10% 0
13 57.3(M) 26 21% 0
Six AceMIF inhibitors (compounds 1–6) were identified from the GenPlus small molecule library and seven structural analogs (compounds 7–13) of
compound 2 were additionally searched from the PubChem database. All compounds were assayed for the inhibition of HPP tautomerase activity
(Ki) (inhibition types: C, competitive; M, mixed; NC, noncompetitive), PBMC migration (percent inhibition at 10 mM) and CD74 binding of AceMIF
IC50, and for worm-killing activity.
aMaximum percentile inhibition is listed due to the limited solubility of the compound.
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8 (4-chloro-N-(furan-2-ylmethyl)-3-[methyl(phenyl)sulfamoyl]ben-
zamide),whichhasnoR1group.This implies that the furfurylamine
group plays an important role in interacting with AceMIF, and its
affinity is significantly reduced when its position is changed to
R2 as in compound 7.
Seven structural analogs of compound 2 were tested in the
CD74 capture assay, PBMC migration assay, and ex vivo worm
survival assay to determine their activities relative to compound
2 (Table 1). Compound 8 significantly inhibited the interaction of
AceMIF with CD74 (IC50 of 3.3 mM), whereas compounds 7 and
9 inhibited only 38% and 15% of AceMIF-CD74 binding, respec-
tively. In the PBMC migration assay, compounds 8 and 9 were
similarly active in inhibiting AceMIF-mediated monocyte migra-
tion relative to compound 2, and compound 7, which is missing
a furfurylamine group, was only half as active as the parentChemistry & Biology 18, 1089–110compound. Interestingly, none of the structural analogs of
compound 2 possessed worm-killing activity. Compound 10
has two methyl groups at R1 position instead of a furfuryl group
and two methyl ethers at R2 and R3 positions.
The structural differences in the furosemide analogs caused
significant changes in their ability to inhibit AceMIF tautomerase
activity. For example, the only chemical difference between
compounds 9 and 11 is the replacement of a methylene group
with a carbonyl oxygen next to the anthranilate nitrogen to
form a peptide bond (of compound 11), resulting in a 4-fold
and 9-fold higher Ki, respectively, compared with compound 2
(Ki 0.56 mM). Compound 12 is structurally similar to compound
11 but has an extra methyl group attached to a ring carbon of
the furan group. This difference results in a 14-fold higher Ki
value compared with that of compound 2. Replacement of the
secondary amine linker with a methylated tertiary amine in1, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1093
Figure 2. Inhibition Assay against the Enzymatic and Biological Activity of AceMIF
(A–C) Representative AceMIF hydroxyphenylpyruvate tautomerase inhibition of (A) compound 2 (competitive), (B) compound 5 (noncompetitive), and (C)
compound 3 (mixed). Nonlinear regression of the initial velocity at various substrate and inhibitor concentrations is shown on the top panel, and Lineweaver-Burk
plots are shown on the bottom panel for each inhibitor.
(D) PBMCmigration inhibition assaywith 8 nMAceMIF in the presence of 10 mMcompound concentration. Migrated cells weremeasured by relative fluorescence
units (RFU) as described in Experimental Procedures. The numbers above the bars are Ki’s (in mM) obtained from the tautomerase inhibition assay. One-letter
codes above the numbers represent the type of enzymatic inhibition: C (competitive), NC (noncompetitive), and M (mixed).
(E) Inhibition of CD74-AceMIF interaction by compound 2. Percent of AceMIF bound to immobilized CD74 in the presence of various concentrations of compound
2 is plotted. Chemical structure of compound 2 is shown next to the plot. The IC50 value was determined based on the plot.
(F) Toxicity of AceMIF-specific inhibitors was determined by observing the survival of cultured A. ceylanicum adult worms. Only three of six compounds revealed
worm-killing activity (>15% toxicity) at a dose of 100 mM.
See also Figure S1.
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The crystal structure of compound 2 indicates this linker is buried
in the active site and replacing the amine proton with a methyl
group would result a steric clash, destabilizing the interaction
between inhibitor and AceMIF. Taken together, these results
show that structural alterations of furosemide (compound 2)
significantly impact the nature of their interaction with the Ace-
MIF protein (and resulting inhibitory activities) and furosemide
provides an excellent pharmacophore for novel anthelminthics.
NKCC1 Flux Assay
The diuretic activity of furosemide in humans makes it unsuitable
as an anti-anthelminthic therapeutic for human use. To deter-
mine whether any of the furosemide analogs inhibited Na-K-Cl1094 Chemistry & Biology 18, 1089–1101, September 23, 2011 ª201symporter (NKCC1), a flux assay measuring the influx of 86Rb
as a surrogate marker of K+ in the presence of furosemide and
its structural analogs was measured (Darman and Forbush,
2002). Bumetanide was used as a positive control of inhibition.
The assay was performed at 10 mM and 100 nM concentrations
of each compound. Only bumetanide and furosemide inhibited
the 86Rb influx, whereas the furosemide analogs did not
(Figure 3).
X-ray Crystallography
Attempts at cocrystallizing full-length AceMIF with the selected
compounds in the original condition or in 500 commercial
conditions were unsuccessful presumably caused by the crystal
packing artifact in the apo crystal structure (Figure S2). Various1 Elsevier Ltd All rights reserved
Figure 3. NKCC1 Flux Assay with Compound 2 and Its Structural
Analogs
Percent inhibition of 86Rb influx into NKCC1 cotransporter-expressed HEK293
cells was measured in presence or absence of the compounds. Bumetanide
was used as a positive control. The assay was performed at 10 mMand 100 nM
compounds (n = 3). Most of the furosemide analogs exhibit negative inhibition
and this is probably because of the low value of the untreated control cells
located at the edge row of the assay plate.
Table 2. Crystallographic Data collection and
Refinement Statistics
C2aMIF:Cmpd2 C2aMIF:Cmpd9
Data collection
Space group P3121 P3121
Cell dimensions
a, b, c (A˚) 86.8, 86.8, 115.5 86.2, 86.2, 114.9
(Alpha), (beta), (gamma) () 90, 90, 120 90, 90, 120
Resolution (A˚) 1.8 2.1
Rmerge 0.088 (0.266)
a 0.087 (0.447)
I/(sigma)I 5.2 (2.7) 8.1 (1.7)
Completeness (%) 94.3 (91.0) 100 (100)
Redundancy 8.8 (9.1) 10.4 (10.2)
Refinement
Resolution (A˚) 1.8 2.1
No. reflections 42,127 29,359
Rwork/Rfree 0.17/0.20 0.16/0.21
No. atoms
Protein 2700 2697
Ligand/metal 123 86
Water 275 262
B-factors
Protein 21.5 20.8
Ligand/metal 29.7 30.2
Water 30.6 29.6
Rmsd
Bond lengths (A˚) 0.033 0.028
Bond angles () 2.260 1.960
A single crystal was used for each structure.
aHighest resolution shell.
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tion. Deletion of two C-terminal residues, Thr117 and Met118
(DC2AceMIF), was the only truncation that resulted in cocrys-
tals, diffracting at 1.8A˚ in space group P3121. The crystal struc-
ture was solved by molecular replacement and refined to R and
Rfree of 17% and 20%, respectively. Electron density generated
without a model of compound 2 shows the inhibitor in the active
site in Figure 4A. The carboxylic acid oxygen (O4) of the anthra-
nilate pharmacophore hydrogen bonds with the side chain
hydroxyl group of Ser63, the backbone nitrogen atom of Ile64,
and the side chain nitrogen atom of Lys32 (Figure 4B). The
second carboxyl oxygen (O5) forms a hydrogen bond with the
nitrogen atom of Pro 1, completing a tight hydrogen-bonding
network with the hydrophilic residues in the active site. The
sulfur atom of Met2 also hydrogen-bonds with the nitrogen of
the furfurylamine group of compound 2. No water-mediated
hydrogen-bonding interaction is visible in the electron density.
Hydrophobic interactions exist between the furfuryl group and
the residues consisting of one half of the active site (Figures
4A and 4B). The sulfonamide group and chloride atom are
exposed to the solvent (Figures 4C and 4D). In contrast to the
fully occupied active site by the furfuryl and carboxyl groups,
there is an unoccupied site (Figures 4C and 4D) adjacent to
the chloride atom, where chemical modifications can be madeChemistry & Biology 18, 1089–110to improve the affinity of this compound for AceMIF. This unoc-
cupied site begins with a hydrophobic groove (Val106, Phe108,
and Val113) and ends with hydrophilic residues (Asn109 and
Thr112).
Compound 9 was also cocrystallized with DC2AceMIF, and its
X-ray diffraction data were collected at 2.1A˚ (Figure 5 and
Table 2). Compound 9 is a structural analog of compound 2
and lacks the solvent-exposed sulfonamide group and chloride
atom. It has a 4-fold higher Ki than that of compound 2. Crystal
structures of AceMIF in complex with compounds 2 and 9 are
superimposed using a maximum likelihood method (Theobald
and Wuttke, 2006), with only protein Ca atoms at the root-
mean-square deviations (rmsd) of 0.11A˚ and show an almost
identical fit of the compounds in the active site (Figure 5C). The
loss of the sulfonamide group and chloride atom from compound
2 results in a nondiuretic compound that retains its inhibition
against AceMIF catalytic and migration activity.DISCUSSION
Aprevious report showed that AceMIF is secreted by adult hook-
worms and competes for binding to the human MIF receptor
in vitro (Cho et al., 2007). Evidence also exists that protozoan
(Leishmania major [Kamir et al., 2008]) and helminth (Brugia
malay [Prieto-Lafuente et al., 2009]) parasite MIFs modulate
host immune responses, presumably through interaction with
mammalian receptors on immune cells. Moreover, the develop-
ment of specific small molecule inhibitors synthesized to
neutralize mammalian MIF has shown significant promise in
their ability to ameliorate inflammatory disease (Al-Abed et al.,
2005; Crichlow et al., 2007; Dabideen et al., 2007). The AceMIF1, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1095
Figure 4. Complex Crystal Structure with Compound 2
(A) Difference in electron density of compound 2 was generated at 3s omitting the inhibitor in the final structure model.
(B) Interaction of compound 2with active site residues. The residues involved in hydrogen-bond (ball and stick) and hydrophobic (spiked hemisphere) interactions
are depicted. Hydrogen-bond distances are present on the green dashed lines.
(C) Compound 2 is shown on the electrostatic surface of AceMIF in an orientation pointing into the active site.
(D) A 90 rotation of panel (C).
In (C) and (D), the two protomers I and II forming the active site are represented in ribbons. The dotted area represents a protein site that could be used by novel
analogs of the parent molecule to form new interactions, increasing the affinity for AceMIF and decreasing the affinity for carbonic anhydrase and the Na-K-Cl
cotransporter.
See also Figures S2–S4.
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ization provides partial protection to the host. The partial protec-
tion could potentially be explained by the presence of two MIF
isoforms in A. ceylanicum (unpublished observation), which has
also been demonstrated for other nematodes (Vermeire et al.,
2008). It is possible that targeting both hookworm MIF proteins
through vaccination or chemotherapy might further improve
host protection. The human MIF tautomerase inhibitor, ISO-1,
does not inhibit AceMIF catalytic nor macrophage migration
activity, indicating the active sites are sufficiently different that
a specific AceMIF small molecule inhibitor could be designed
or discovered (Cho et al., 2007). Taken together, these studies
support the rationale that targeting AceMIF represents a viable
strategy to reduce hookworm pathogenesis and disease.
High Throughput Screening and Drug Repositioning
Among almost 1000 FDA-approved drugs or other bioactive
compounds for the HTS screen, compounds that showed1096 Chemistry & Biology 18, 1089–1101, September 23, 2011 ª201R60% inhibition of the L-dopachrome-methyl ester tautomer-
ase activity of AceMIF in the initial screen were subjected to
a more comprehensive analysis to characterize the Ki, which
varied from submicromolar to hundreds of micromolar. The
AceMIF-specific inhibitors identified in the HTS screen were
characterized in other AceMIF assays. For example, plate-based
chemotaxis and competition enzyme-linked immunosorbent
assay experiments to probe the effect of inhibitor compounds
on AceMIF-mediated cell migration and CD74 receptor binding
were studied. Finally, all six compounds and selected analogs
were tested to determine toxicity against A. ceylanicum in an
ex vivo assay (Cappello et al., 2006). Only compounds 2, 3,
and 4 (or their metabolites) demonstrated any worm-killing
activity, which was clearly independent of any human target.
Interestingly, compound 4 (pyrantel pamoate) is a neuromuscular
depolarizing agent known to cause paralysis in helminthes, re-
sulting in parasite expulsion through a mechanism involving
inhibition of parasite cholinesterase. Identification of pyrantel1 Elsevier Ltd All rights reserved
Figure 5. Complex Crystal Structure with Compound 9, A Structural Analog of Compound 2
(A) and (B) were generated in the same manner with those of compound 2 in Figure 3. (C) is the superposition of compounds 2 and 9 at the catalytic site. See also
Figures S2 and S4.
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compoundmay havemultiple targets within parasitic nematodes
that are responsible for its anthelminthic properties. Among the
six compounds that were identified, only compound 1 (sodium
meclofenamate), an anti-inflammatory therapeutic that inhibits
cyclooxygenase pathway (Matsell et al., 1994), might be reposi-
tioned as anthelminthic. The trough and peak levels of this drug
are 0.2 mg/ml and 15 mg/ml (0.6 mM and 45 mM), respectively, at
an oral dose of 100 mg (Conroy et al., 1991). The trough level is
higher than the Ki for catalytic activity, and 10 mM of sodium
meclofenamate would inhibit 100% of macrophage migration
(Figure 1D and Table 1). The potential adverse effect of sodium
meclofenamate includes impeding the immune system, which
may prevent an appropriate response to hookworm infection. It
is therefore very important to monitor the efficacy and adverse
effects of compound 1 in the Syrian hamster model of hookworm
disease and any future clinical trials in humans.
Ki and IC50 for Receptor Binding,MacrophageMigration,
and Hookworm Survival
There was no strict interdependence among the Ki of enzymatic
activity and IC50 values for receptor binding and chemotaxis inhi-
bition. This paradox does not only involve the inhibitors in this
study but also protein mutagenesis studies (Lubetsky et al.,
2002; Swope et al., 1998) and mice knockin of a tautomerase
null, Pro1-to-Gly MIF protein (P1G-MIF) replacing the endoge-
nous mif gene (Fingerle-Rowson et al., 2009), that show a large
decrease in catalytic activity and have a smaller decrease in bio-Chemistry & Biology 18, 1089–110logical activity. This suggests that protein-protein interactions
are critical for the immunological function of MIF rather than
the catalytic activity of MIF (Fingerle-Rowson et al., 2009). Taken
together, these observations imply that MIF-receptor binding
occurs at or near the tautomerase site and that some small
molecule active site inhibitors have chemical moieties that inter-
fere with the MIF-receptor interactions. In this regard, structural
studies indicate that compound 2, which has a sulfonamide
group and chloride atom that protrude from the active site and
make no interaction with AceMIF, inhibits that interaction
between AceMIF and human MIF receptor. These two groups
are removed in compound 9. X-ray crystallography indicates
that the interactions within the active site are retained, but this
compound does not inhibit AceMIF-human MIF receptor
interactions.
The ex vivo worm survival assay (at the single concentration of
100 mM) to test the toxicity of inhibitors to the parasite showed
no clear relationship between inhibition of AceMIF enzymatic
activity and A. ceylanicum killing. Again, this implies that the inhi-
bition of the catalytic activity of AceMIF does not affect the
pathology induced by the protein during hookworm infection.
These incongruent results may be explained in part by the multi-
functional nature of MIF proteins: (1) An active site that catalyzes
a chemical reaction, and (2) a binding site near the active site that
interacts with the MIF receptor. By selecting for inhibitors of tau-
tomerase activity in the HTS, we have identified compounds
effective in inhibiting the catalytic activity, including a few
compounds that also disrupt MIF-receptor interactions.1, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1097
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Compound 2 (furosemide) exhibited submicromolar Ki (0.56 mM)
and IC50 (0.33 mM) values for the enzymatic and receptor binding
inhibition activities, respectively, and inhibition of AceMIF-medi-
ated monocyte chemotaxis (IC50 of 1 mM). In addition, it was also
toxic to adult worms (50% killing relative to controls). Furose-
mide is a diuretic that blocks the Na-K-Cl cotransporter (Kirken-
dall and Stein, 1968; Puschett, 1981). It has an anthranilate scaf-
fold, as does meclofenamate, and can be represented by
a benzene scaffold for a broader structural analog search. A furo-
semide-based search of commercially available reagents with
decreased Tanimoto coefficients yielded seven structurally
related compounds (compounds 7–13) to test the significance
of each R-group (see Table 1) in AceMIF assays and in inhibiting
the Na-K-Cl symporter. Kinetic assays revealed higher Ki values
for all seven analogs, ranging from 5–247 mM depending on the
R-groups. Compounds 8 and 9 possessed similar activity to
compound 2 in their ability to inhibit AceMIF-mediated PBMC
migration (82% inhibition for both). Compound 8 also acts as
an antagonist in solution with AceMIF, preventing its binding to
CD74. However, none of the compound 2 analogs showed hook-
worm-killing activity, nor did any of the seven analogs inhibit the
Na-K-Cl symporter.
Crystallographic analysis of compounds 2 and 9 complexed to
AceMIF was performed to more fully understand the interaction
of these compounds with AceMIF and to form the basis of future
structure-based drug design studies. A superposition of the two
structures is shown in Figure 5C and reveals an excellent overlay
of the two compounds in the active site. The solvent accessible
sulfonamide and chloride R-groups have no interactions with
the protein for compound 2 and result in a marginal difference
in Ki for compound 9, which does not contain either of these
R-groups.
We also compared the crystal structures of AceMIF-
compound 2 with human MIF-ISO-1 and with carbonic anhy-
drase-compound 2 to reveal the basis of these interactions (Fig-
ure S3). The specificity of the ISO-1 inhibitor for human MIF
relative to AceMIF is based on different residues for one side
(half) of the active site. In the carbonic anhydrase-compound 2
(PDB ID 1Z9Y) crystal structure (Puschett, 1981) the sulfonamide
and the chloride make important binding interactions with
carbonic anhydrase (Figure S4), whereas in the AceMIF co-
complex these two R-groups point out of the active site into
the solvent and make no interactions with the protein (Figure 4).
In summary, the AceMIF vaccination study provides the
‘‘proof-of-concept’’ for targeting a helminth immunomodulator
with small molecule compounds. The high throughput screen
identified six bioactive molecules. One AceMIF-specific inhibi-
tor, sodium meclofenamate, could be repositioned as a hook-
worm therapeutic with the caveat that its adverse effects do
not interfere with the immune response during treatment in
animal model studies. Functional and structural studies of furo-
semide led to a pharmacophore and SAR studies. The differen-
tial effects of the compounds identified from the screen and the
furosemide analogs will be useful in probing the relative signifi-
cance of AceMIF-induced activities in the pathology of hook-
worm infection in vivo. This information will be useful for future
structure-based drug design.1098 Chemistry & Biology 18, 1089–1101, September 23, 2011 ª201SIGNIFICANCE
Hookworm disease is caused by intestinal, blood-feeding
nematode parasites and infects nearly 600 million people
worldwide, causing frequent morbidity, particularly in preg-
nant women and children. Reports of increasing treatment
failure rates in human populations have raised concerns
about potential anthelminthic resistance, especially against
the benzimidazoles class of deworming drugs (Albonico
et al., 2004). In the present study we screened a library of
bioactive materials against an Ancylostoma ceylanicum
homolog of macrophage migration inhibitory factor
(AceMIF) and identified six inhibitors that could either be
used as additional therapeutics for hookworm disease or
scaffolds to design more potent compounds. Human MIF
is a pro-inflammatory protein that has a variety of functions.
AceMIF also possesses some of these functions, whichmay
help the worm evade the host immune response by serving
as a partial agonist for the MIF receptor. Six small molecule
inhibitors of AceMIF were characterized for their effects on
catalytic, receptor binding, and chemotactic activities of
AceMIF. An ex vivo worm-killing assay was performed to
test whether any of the HTS-identified inhibitors possessed
anthelminthic activity. Some of these compounds already
target hookworm disease by other mechanisms, which
nowmay include inhibition of AceMIF function. Furosemide,
a diuretic, exhibited the most potent combination of inhibi-
tory activities relative to other identified compounds. Struc-
ture-activity studies of furosemide analogs lacking diuretic
activity and crystallographic characterization of furosemide
and a nondiuretic analog bound to AceMIF provide addi-
tional structural information that can be used to improve
potency without reintroducing diuretic activity.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in Supplemental Experimental
Procedures.
Materials
AceMIF was purified as described previously (Cho et al., 2007). HPP, L-3,4-di-
hydroxyphenylalanine methyl ester hydrochloride (methyl L-DOPA hydrochlo-
ride), and sodium (meta) periodate were purchased from Sigma (St. Louis,
MO). Chemical analogs were obtained from Sigma, Ambinter (Paris, France),
and the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov).
AceMIF Immunization
For systemic immunization, groups of five male LVG hamsters (Charles River,
Wilmington, MA) were immunized subcutaneously with 100 mg of recombinant
AceMIF protein using the adjuvant aluminum hydroxide (alum, Alohydrogel,
HCI Biosector, Frederickssund, Denmark). Control animals were immunized
with alum alone. The animals were to be boosted subcutaneously twice at
3 week intervals with the same dose. One week after the third immunization,
hamsters were infected with 100 A. ceylanicum L3 by oral gavage. For each
of the vaccination groups studied, hamsters were weighed every other day
and serum hemoglobin was measured using a commercially available kit
(Sigma). Animals were followed for 40 days postinfection, and recombinant
AceMIF protein–immunized animals were compared with adjuvant unimmu-
nized and uninfected controls. For these studies, statistical analyses were
carried out using the StatView, version 4.51, statistical software package
(Abacus Concepts, Inc., Piscataway, NJ). Pairwise comparisons were per-
formed using Student’s t test. For multiple group comparisons, analysis of1 Elsevier Ltd All rights reserved
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ence as a posttest. P values of < 0.05 were considered significant.
High Throughput Screening for AceMIF Inhibitors
AceMIF was screened against a small chemical library at the Center for Chem-
ical Genomics at Yale University. The Gen-Plus chemical library was obtained
from MicroSource Discovery Systems Inc. and contains 960 bioactive
compounds including marketed pharmaceuticals (Supplemental Experimental
Procedures).
Measurement of Ki
The MIF keto-enol HPP isomerase activity was used to obtain Ki values for
each inhibitor identified by HTS (Supplemental Experimental Procedures).
PBMC Migration Inhibition Assay
A preliminary peripheral blood mononuclear cell migration assay was per-
formed as previously described (Cho et al., 2007) with one concentration of
small molecule compounds (10 mM) and one concentration of AceMIF
(8 nM). Cell migration was assessed using the QCM chemotaxis 96 well assay
(Chemicon, Billerica, MA). Fluorescence of migrated cells wasmeasured using
the 480/520 nm filter set of a Tecan Infinite M200 plate reader (Durham, NC).
Results are graphically represented in relative fluorescence units (RFU) of
experimental wells after subtraction of negative (no AceMIF) and background
controls (no cells). A more comprehensive dose-response migration assay of
PBMC chemotaxis was used to determine the IC50 of compound 2 (Figure S1).
MIF Receptor CD74 Capture Assay
Because of the sensitivity of the capture assay to DMSO, 10 mM of each
compound in 100% DMSO was diluted to a final DMSO concentration of
<0.04% DMSO before assaying. To elucidate CD74 inhibition by the
compounds, a 96 well Immunoplate (NUNC, Rochester, NY) was coated
with soluble CD74 ectodomain (sCD7473-232) as described (Leng et al.,
2003). The inhibitors were preincubated with biotinylated AceMIF (2 ng/ml)
prepared using the Biotin Labeling Kit (Roche Molecular Biochemicals, Nutley,
NJ) for 1 hr at room temperature in the dark. Immobilized sCD7473-232 was
mixed and incubated with the preincubated inhibitor-biotinylated AceMIF at
4C overnight. The plate was washed with 250 ml/well Tween-20, Tris-buffered
saline (Thermo Scientific, Pittsburgh, PA). The biotinylated AceMIF was de-
tected by streptavidin-alkaline phosphatase (R&D Systems, Minneapolis,
MN) followed by color development with 60 ml/well of p-nitrophenylphosphate
(Sigma) observed at 405 nm.
Toxicity against A. ceylanicum Ex Vivo
A. ceylanicumworms were removed from the small intestine of infected Syrian
hamsters (Bungiro et al., 2001) and cultured in hookworm culture medium
(HCM) consisting of RPMI 1640 medium, 50% FCS, 20 U/20mg/ml penicillin/
streptomycin, 10 mg/ml Fungizone (Bristol-Myers Squibb, New York, NY) as
described (Cappello et al., 2006). The susceptibility of A. ceylanicum to
AceMIF-specific inhibitors was evaluated by culturing wells of adult worms
(10 worms/well, 2 wells/ treatment) in the presence of 100 mM concentration
of each compound. Control wells contained equivalent volumes of DMSO
and/or albendazole (Sigma), the current standard for treating hookworm infec-
tions. At 24 hr intervals the wells were evaluated by light microscopy to deter-
mine the percentage of live vs. dead worms.
Structure-Activity Relationships
The structural similarity search was performed in the PubChem small molecule
database of the National Center for Biotechnology Information (NCBI) with
Tanimoto coefficients (structural similarity index) of 80 and 85. Seven structural
analogs (compounds 7–13) of compound 2 were available for further studies
(Table 1).
Flux Experiment
Target specificity of the furosemide analogs was tested against the Na-K-Cl
cotransporter NKCC1 in a flux experiment as previously described (Darman
and Forbush, 2002). In this study, we used low chloride hypotonic medium
to preactivate NKCC1 for 40 min, then 20 mM Cl medium (135 mM NaCl,
5mMK+, 124mMgluconate, 1 mMMg+, 1 mMCa+) for a 10min preincubationChemistry & Biology 18, 1089–110with the testing compounds, and finally a 1.1-min flux in the regular flux
medium, consisting of 135 mM NaCl, 5 mM RbCl, 1 mM CaCl2/MgCl2, 1 mM
Na2HPO4/Na2SO4, 1 mCi/ml 86Rb, 10-4 M ouabain, and 15 mM NaHEPES,
pH 7.4, without inhibitors and at two concentrations (10 mMand 100 nM) of bu-
metanide, furosemide, and analogs.
X-ray Crystallography
The carboxyl terminal residues Thr117 and Met118 were truncated
(DC2AceMIF) to overcome a crystal-packing artifact that hinders cocrystalliza-
tion of the selected inhibitors. DC2AceMIF (32.5 mg/ml) was crystallized in
complex with 2.5 mM of compound 2 or 9 in 0.1 M imidazole, pH 8.0, 0.16–
0.24 M zinc acetate, and 15%–25% PEG3000. Crystals were grown to
400 mm at 18C within two weeks (Supplemental Data).ACCESSION NUMBERS
The coordinates for the structure of AceMIF and furosemide complex is 3RF4
and for the structure of the AceMIF and compound 9 complex is 3RF5, and
have been deposited in the Protein Data Bank.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.chembiol.2011.07.011.
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